期刊
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
卷 6, 期 4, 页码 313-323出版社
FUTURE MEDICINE LTD
DOI: 10.2217/cer-2016-0085
关键词
comparative effectiveness; delayed-release dimethyl fumarate; glatiramer acetate; multiple sclerosis
资金
- Biogen
- Genzyme
- Novartis
- Consortium of MS Centers grant
- D3 (Drug Discovery and Development)
- Jannsen Pharmaceuticals
- Klein-Buendel Incorporated
- Medimmune
- Opexa Therapeutics
- Receptos
- Roche
- EMD Serono
- Teva Pharmaceuticals
- Transparency Life Sciences
- MedDay
- Questcor
- Teva
- Xenoport
Aim: Using matching-adjusted indirect comparison, we compared efficacy outcomes in patients with relapsing-remitting multiple sclerosis treated with delayed-release dimethyl fumarate (DMF) or glatiramer acetate (GA). Materials & methods: An indirect comparison of DMF (patient-level data) and GA (aggregate data) was conducted, with average baseline characteristics of DMF patients weighted to match those for GA patients. Direct comparison of DMF and GA was conducted in CONFIRM. Final results pooled the indirect and direct comparisons using meta-analysis. Results: After matching, baseline characteristics were balanced between DMF and GA patients. Compared with GA, efficacy was significantly in favor of DMF as measured by annualized relapse rate (rate ratio: 0.76; 95% CI: 0.57-1.00; p = 0.0474) and 12-week confirmed disability progression (risk ratio: 0.59; 95% CI: 0.46-0.76; p < 0.0001). Conclusion: DMF demonstrated superior clinical efficacy versus GA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据